Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06592560
Asprosin in Breast Cancer
Sponsor: Marina Hanna Thabet Ghobrial
View on ClinicalTrials.gov
Summary
To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis
Official title: Diagnostic Value of Asprosin As a Biomarker in Breast Cancer
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
84
Start Date
2024-10
Completion Date
2025-10
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
DEVICE
ELISA
Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).